Silexion Therapeutics completes toxicology studies for SIL204

Silexion Therapeutics (SLXN) announced the successful completion of toxicology studies for SIL204, the Company’s next-generation RNA silencing therapy targeting mutated KRAS oncogenes, ahead of its planned Phase 2/3 clinical trial in locally advanced pancreatic cancer. Ilan Hadar, Chairman and Chief Executive Officer of Silexion, commented: “Results from the toxicology studies have cleared us to maintain our planned timelines to initiate SIL204’s Phase 2/3 clinical trial in pancreatic cancer. We have recently secured our CRO partner for the trial and continue to prepare regulatory submissions to both Israel’s Ministry of Health and Germany’s Health Authority. SIL204’s preclinical package has shown remarkable potential as a cancer treatment, offering an innovative modality – stopping mutated, cancer-driving proteins before they are expressed. We are eager to prove this potential in the clinic and bring SIL204 to patients who could benefit from this treatment. We remain on track to initiate the first stage of SIL204’s advanced clinical development in the second quarter of 2026.”